

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

BRANTS, Johan Philippe Emile  
DE CLERCQ BRANTS & PARTNERS CV  
E. Gevaertdreef 10a  
B-9830 Sint-Martens-Latem  
BELGIQUE

## PCT

WRITTEN OPINION  
(PCT Rule 66)

Date of mailing (day/month/year) <span style="float: right;">31.08.2005</span>	
Applicant's or agent's file reference ABL-017-PCT	<b>REPLY DUE</b> <span style="float: right;"><b>within 3 month(s)</b> from the above date of mailing</span>
International application No. PCT/BE 03/00189	International filing date (day/month/year) 07.11.2003
Priority date (day/month/year) 07.11.2003	
International Patent Classification (IPC) or both national classification and IPC C07K16/28, A61K39/395, C12N15/13, C07K19/00, A61P35/00, C07K16/18, G01N33/577	
Applicant ABLYNX N.V. et al.	


1. This written opinion is the **first** drawn up by this International Preliminary Examining Authority.
2. This opinion contains indications relating to the following items:
  - I ☒ Basis of the opinion
  - II ☐ Priority
  - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
  - IV ☐ Lack of unity of invention
  - V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
  - VI ☐ Certain documents cited
  - VII ☐ Certain defects in the international application
  - VIII ☐ Certain observations on the international application
3. The applicant is hereby **invited to reply** to this opinion.
 

**When?** See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

**How?** By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

**Also:** For an additional opportunity to submit amendments, see Rule 66.4.  
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.  
For an informal communication with the examiner, see Rule 66.6.

**If no reply is filed**, the international preliminary examination report will be established on the basis of this opinion.
4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 07.03.2006

Name and mailing address of the international preliminary examining authority:   European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Authorized Officer <b>Le Flao, K</b> Formalities officer (incl. extension of time limits) <b>Wallentin, M</b> Telephone No. +31 70 340-3991
---	---



**I. Basis of the opinion**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed"*):

**Description, Pages**

1-57 as originally filed

**Claims, Numbers**

1-45 as originally filed

**Drawings, Figures**

1-9 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☒ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:

☐ the entire international application,

☐ claims Nos.

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (specify):

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. 14-16 (totally) and 18,19, 33 (partially)

2. A written opinion cannot be drawn due to the failure of the nucleotide and/or amino acid sequence listing to comply with the Standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the Standard.

☐ the computer readable form has not been furnished or does not comply with the Standard.

**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Claims	
Inventive step (IS)	Claims	1-13,17-45
Industrial applicability (IA)	Claims	

2. Citations and explanations

**see separate sheet**

**Re Item V**

Reference is made to the following documents:

- D1: US 2002/058033 A1 (Bonner J et al) 16 May 2002
- D2: ARBABI GHAHROUDI M ET AL: "Selection and identification of single domain antibody fragments from camel heavy-chain antibodies" FEBS LETTERS, vol. 414, no. 3, 15 September 1997, pages 521-526, XP002069903
- D3: US 2003/092892 A1 (Howell S et al) 15 May 2003
- D4: CORTEZ-RETAMOZO V ET AL: "Efficient tumor targeting by single-domain antibody fragments of camels" INTERNATIONAL JOURNAL OF CANCER, vol. 98, no. 3, 20 March 2002, pages 456-462, XP002248403

Claims 1-13 and 17-45 are novel since they relate to single domain antibody against EGFR and uses thereof, which are not disclosed in any of the cited documents.

**1. Lack of Inventive step: claims 1-9, 17-45**

The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claim 1 does not involve an inventive step in the sense of Article 33(3) PCT.

The document **D1** is regarded as being the closest prior art to the subject-matter of claim 1, and discloses (the references in parentheses applying to this document) anti EGFR human single chain antibodies (scFv, §45) isolated by screening phage library. Such antibodies are used to detect breast cancer tumours (§93).

The subject-matter of claim 1 therefore differs from these known antibodies in that it comprises at least one single domain antibody, with specific sequences. The effect of the difference is that it is an alternative form of antibody.

The problem to be solved by the present invention may therefore be regarded as the provision of an alternative form of anti EGFR antibodies. The solution proposed in claim 1 of the present application cannot be considered as involving an inventive step (Article 33(3) PCT) for the following reasons.

Document **D2** discloses the immunisation of dromedary with tetanus toxoid and lysozyme, the isolation of mRNA from the blood, the construction of a library and the selection of soluble VHH fragments. The interest of such VHHs for preparing multivalent binders having an increased avidity is mentioned (p.521, right-hand column, §4,5 ; p.522, left-hand column ; p.525, right-hand column, §3). It is therefore considered that the skilled person when trying to solve the problem posed would apply the teaching of D2 for obtaining a VHH antibody anti EGFR. The preparation of VHHs antibodies itself is not considered inventive since it is known from many documents published before the filing date describing such a method (see also WO03/054016). Applying a known technique for preparing antibodies to another particular protein, here EGFR, is not considered to require inventive skills.

However part of claim 2 is considered as involving an inventive step for the following reason. The fact that in example 7 it has been shown that recombinant nanobody EGFRIIIa42 is able to internalize Her-14 but not 3T3 cells is a particular property supporting the inventive step of part of claim 2. Should the applicant submit data showing unexpected properties to the 22 anti EGFR disclosed in the application, an inventive step may be recognized for claim 2. Otherwise restriction to the particular example is required.

Dependent claims 3 and 4 dealing with polypeptide further comprising a single domain antibody directed against a serum protein or against IFN-gamma, TNF-alpha, IFN-gamma receptor or TNF-alpha receptor do not appear to involve an inventive step since document D2 discloses the interest of having multivalent VHHs.

Dependent claims 5-9 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of inventive step. The same reasoning applies, mutatis mutandis, to the subject-matter of the corresponding independent claim 17, which therefore is also considered not inventive.

Claims 18-36 relating to the therapeutical use and the diagnostic use of the antibodies is anticipated by D1 which discloses the detection of breast cancer with anti EGFR antibodies and describes the therapeutical uses for treating cancers. Such claims are therefore not considered to involve an inventive step. Neither are claims 37-45 related to the use, the method for producing a polypeptide, a kit and a therapeutic composition.

## **2. Inventive step and support : claims 10-13**

Claims 10-12 relating to a method of identifying an agent that modulates the binding of an anti-EGFR polypeptide of any of claims 1 to 9 and claim 13 relating to a kit for screening for agents that modulate EGFR - mediated disorders are speculative, not supported as required by Article 6 PCT and not disclosed in the description as required by Article 5 PCT. These claims are attempting to solve a hypothetical problem without providing a solution. As a consequence it is not considered that such claims involve inventive step.

## **3. Clarity**

Claims 1-9 are not supported by the description as required by Article 6 PCT, as their scope is broader than justified by the description and drawings. The reasons therefor are the following: the examples deal with Camelidae VHHs antibody against EGFR. The description and example convey the impression that anti EGFR polypeptide comprising at least one single domain antibody against EGFR can only be prepared as camelidae VHHs and no alternative forms are envisaged. Considering using such a terminology is possible the term "an anti-EGFR polypeptide comprising at least" is too vague and the claims are not supported by the description as required by Article 6 PCT.

Claims 8 and 9 do not meet the requirements of Article 6 PCT in that the matter for which protection is sought is not clearly defined. The following functional statements do not enable the skilled person to determine which technical features are necessary to perform the stated function: homologous sequence, a functional portion.